Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.47 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | GSR | P00390 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ARG1 | P05089 | 3/20 | 0.32 |
| ▸ | ARG2 | P78540 | 3/20 | 0.32 |
| ▸ | GLP1R | P43220 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24788159 | 0.88 | OTC (0.40) | NOD1OTCGSR | |
| SCHEMBL26076120 | 0.86 | OTC (0.47) | NOD1OTCGSRTDP1ARG1 | |
| SCHEMBL23817766 | 0.77 | OTC (0.40) | NOD1OTCGSR | |
| SCHEMBL26076119 | 0.76 | GSR (0.47) | NOD1OTCGSRTDP1ARG1 | |
| SCHEMBL16309272 | 0.76 | SLC1A2 (0.43) | NOD1OTCGSR | |
| SCHEMBL15424356 | 0.76 | SLC1A2 (0.43) | NOD1OTCGSR | |
| SCHEMBL24229748 | 0.75 | OTC (0.49) | NOD1OTCGSRTDP1GLP1R | |
| SCHEMBL17346257 | 0.75 | OTC (0.49) | NOD1OTCGSRTDP1GLP1R | |
| SCHEMBL21738833 | 0.75 | OTC (0.49) | NOD1OTCGSRTDP1GLP1R | |
| SCHEMBL29221102 | 0.75 | OTC (0.49) | NOD1OTCGSRTDP1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210284694-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | MERCK SHARP & DOHME LLC | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284694-A1 | CYCLIC POLYPEPTIDES FOR PCSK9 INHIBITION | PCSK9, LDLR, PCSK7 | NOD1 2513/4885OTC 3433/4885GSR 4634/4885 |
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | NOD1 2513/4885OTC 3433/4885GSR 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.